Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

2.

Drosophila models of FOP provide mechanistic insight.

Le V, Anderson E, Akiyama T, Wharton KA.

Bone. 2017 Nov 8. pii: S8756-3282(17)30417-9. doi: 10.1016/j.bone.2017.11.001. [Epub ahead of print] Review.

PMID:
29128351
3.

[Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)].

Katagiri T.

Clin Calcium. 2010 Aug;20(8):1204-11. doi: CliCa100812041211. Review. Japanese.

PMID:
20675931
4.

Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.

Luo Y, Alsamarah A, Zhang K, Hao J.

Curr Mol Med. 2016;16(1):4-11. Review.

PMID:
26695699
5.

Fibrodysplasia ossificans progressiva: clinical and genetic aspects.

Pignolo RJ, Shore EM, Kaplan FS.

Orphanet J Rare Dis. 2011 Dec 1;6:80. doi: 10.1186/1750-1172-6-80. Review.

6.

Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis.

Kaplan FS, Chakkalakal SA, Shore EM.

Dis Model Mech. 2012 Nov;5(6):756-62. doi: 10.1242/dmm.010280. Review.

7.

Fibrodysplasia ossificans progressiva.

Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM.

Best Pract Res Clin Rheumatol. 2008 Mar;22(1):191-205. doi: 10.1016/j.berh.2007.11.007. Review.

8.

Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP).

Kaplan FS, Shen Q, Lounev V, Seemann P, Groppe J, Katagiri T, Pignolo RJ, Shore EM.

J Bone Miner Metab. 2008;26(6):521-30. doi: 10.1007/s00774-008-0879-8. Epub 2008 Nov 1. Review.

9.

[Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].

Katagiri T, Kamizono J, Nakashima Y, Kitoh H, Susami T, Haga N.

Clin Calcium. 2010 Oct;20(10):1510-7. doi: CliCa101015101517. Review. Japanese.

PMID:
20890033
10.

[BMP signaling and bone formation].

Katagiri T.

Clin Calcium. 2012 Nov;22(11):1677-83. doi: CliCa121116771683. Review. Japanese.

PMID:
23103811
11.

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.

Kaplan FS, Glaser DL, Pignolo RJ, Shore EM.

Expert Opin Biol Ther. 2007 May;7(5):705-12. Review.

PMID:
17477807
12.

Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.

Shore EM, Kaplan FS.

Curr Osteoporos Rep. 2011 Jun;9(2):83-8. doi: 10.1007/s11914-011-0046-3. Review.

13.

Granting immunity to FOP and catching heterotopic ossification in the Act.

Kaplan FS, Pignolo RJ, Shore EM.

Semin Cell Dev Biol. 2016 Jan;49:30-6. doi: 10.1016/j.semcdb.2015.12.013. Epub 2015 Dec 17. Review.

14.

[Fibrodysplasia ossificans progressiva and osteoimmunology].

Katagiri T.

Clin Calcium. 2016 May;26(5):691-8. doi: CliCa1605691698. Review. Japanese.

PMID:
27117614
15.

Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.

Pignolo RJ, Shore EM, Kaplan FS.

Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:437-48. Review.

16.

Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Pacifici M, Shore EM.

Cytokine Growth Factor Rev. 2016 Feb;27:93-104. doi: 10.1016/j.cytogfr.2015.12.007. Epub 2015 Dec 28. Review.

17.

Dysregulation of the BMP-4 signaling pathway in fibrodysplasia ossificans progressiva.

Kaplan FS, Fiori J, DE LA Peña LS, Ahn J, Billings PC, Shore EM.

Ann N Y Acad Sci. 2006 Apr;1068:54-65. Review.

PMID:
16831905
18.

Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis.

Kaplan FS, Lounev VY, Wang H, Pignolo RJ, Shore EM.

Ann N Y Acad Sci. 2011 Nov;1237:5-10. doi: 10.1111/j.1749-6632.2011.06195.x. Review.

19.

Genetic abnormalities in fibrodysplasia ossificans progressiva.

Miao J, Zhang C, Wu S, Peng Z, Tania M.

Genes Genet Syst. 2012;87(4):213-9. Review.

20.

Variable signaling activity by FOP ACVR1 mutations.

Haupt J, Xu M, Shore EM.

Bone. 2017 Oct 31. pii: S8756-3282(17)30393-9. doi: 10.1016/j.bone.2017.10.027. [Epub ahead of print] Review.

PMID:
29097342

Supplemental Content

Support Center